about
Changes in serum levels of lipopolysaccharides and CD26 in patients with Crohn's disease.Risk factors for complications after ileocolonic resection for Crohn's disease with a major focus on the impact of preoperative immunosuppressive and biologic therapy: A retrospective international multicentre study.Recommendations on the use of biosimilars by the Brazilian Society of Rheumatology, Brazilian Society of Dermatology, Brazilian Federation of Gastroenterology and Brazilian Study Group on Inflammatory Bowel Disease--Focus on clinical evaluation of mPOSTOPERATIVE APPROACH FOR CROHN'S DISEASE: THE RIGHT THERAPY TO THE RIGHT PATIENT.Results of the Fifth Scientific Workshop of the ECCO [II]: Clinical Aspects of Perianal Fistulising Crohn's Disease-the Unmet Needs.Economic impact of expanded use of biologic therapy for the treatment of rheumatoid arthritis and Crohn's disease in Argentina, Brazil, Colombia, and Mexico.Factors affecting the incidence of early endoscopic recurrence after ileocolonic resection for Crohn's disease: a multicentre observational study.Preoperative use of anti-tumor necrosis factor therapy in Crohn's disease: promises and pitfalls.Special situations in inflammatory bowel disease: First Latin American consensus of the Pan American Crohn's and Colitis Organisation (PANCCO) (Second part).Tumor Necrosis Factor Alpha Inhibitors Did Not Influence Postoperative Morbidity After Elective Surgical Resections in Crohn's Disease.Biosimilars in inflammatory bowel diseases: an important moment for Brazilian gastroenterologists.Direct retrospective comparison of adalimumab and infliximab in preventing early postoperative endoscopic recurrence after ileocaecal resection for crohn's disease: results from the MULTIPER database.Disease duration did not influence the rates of loss of efficacy of the anti-TNF therapy in Latin American Crohn’s disease patients.Anal Squamous Cell Carcinoma: An Infrequent Challenge in the Management of Ulcerative Colitis Under Combination Therapy.Research in inflammatory bowel diseases in Latin America: a challenge ahead.Is fecal calprotectin useful for monitoring endoscopic disease activity in patients with postoperative Crohn's disease?Preoperative Vedolizumab and Postoperative Outcomes in Inflammatory Bowel Disease: Does Smoke Always Mean Fire?ADALIMUMAB FOR ULCERATIVE COLITIS: RESULTS OF A BRAZILIAN MULTICENTER OBSERVATIONAL STUDY.Modern management of perianal fistulas in Crohn's disease: future directions.SAFETY PROFILE OF ANTI-TNF THERAPY IN CROHN'S DISEASE MANAGEMENT: A BRAZILIAN SINGLE-CENTER DIRECT RETROSPECTIVE COMPARISON BETWEEN INFLIXIMAB AND ADALIMUMAB.Adalimumab and postoperative complications of elective intestinal resections in Crohn's disease: a propensity score case-matched study.Postoperative topical analgesia of hemorrhoidectomy with policresulen and cinchocaine: a prospective and controlled study.Glucose Metabolism Parameters and Post-Prandial GLP-1 and GLP-2 Release Largely Vary in Several Distinct Situations: a Controlled Comparison Among Individuals with Crohn's Disease and Individuals with Obesity Before and After Bariatric Surgery.Clinical utility of ustekinumab in Crohn's disease.Comparison of time until elective intestinal resection regarding previous anti-tumor necrosis factor exposure: a Brazilian study on patients with Crohn's disease.Fluorescence angiography during transanal trans-stomal proctectomy and ileal pouch anal anastomosis: a video vignette.Staging surgery for ulcerative colitis: more than meets the eye.Decision tree construction and cost-effectiveness analysis of treatment of ulcerative colitis with pentasa® mesalazine 2 g sachet.Effect of anti-TNF-α on peritoneal endometrial implants of rats.ANVISA APPROVES THE FIRST BIOSIMILAR MONOCLONAL ANTIBODY BASED ON COMPARABILITY IN BRAZIL.THE APPROVAL OF VEDOLIZUMAB FOR THE MANAGEMENT OF INFLAMMATORY BOWEL DISEASES IN BRAZIL: the beginning of a new biological era.Obesity and Crohn's disease: what comes first, the egg or the chicken?Diagnosis and treatment of inflammatory bowel disease: First Latin American Consensus of the Pan American Crohn's and Colitis Organisation.Long Time from Diagnosis to Surgery May Increase Postoperative Complication Rates in Elective CD Intestinal Resections: An Observational Study.The old versus the new: which do you keep in postoperative Crohn's disease?Vedolizumab and early postoperative complications in nonintestinal surgery: a case-matched analysis.Letter: can a specific surgical approach reduce post-operative recurrence in Crohn's disease?Hypoalbuminemia as a risk factor for thromboembolic events in inflammatory bowel disease inpatientsMotor neuropathy with multiple conduction blocks associated with TNF-alpha antagonistAnal Fistula Plug for Perianal Fistulising Crohn's Disease: an Important Trial for Inflammatory Bowel Disease Surgeons
P50
Q33819500-8C36FE81-E5AD-4128-AF09-E282840C977EQ37744596-EECF3181-88D9-4263-ABDC-6A4D99DA3CB8Q38455953-D52B1836-4AC1-45A2-A0FE-03E8D2CB631BQ38621576-6509CC2A-012A-4F99-9A6B-8CC9FBA82ED1Q38716515-0EB98A3E-BFE5-4294-B4D7-D3EB69DA96E5Q38845478-9AFEC3A4-EBA9-46EC-9AF8-000800EDB854Q39108648-214D5AA0-8E01-4391-A25D-707E3DFF14E3Q39316824-4F9CC638-BB86-43E0-B056-E2CC1681F45DQ40288106-D239340D-F46A-4BC2-826C-40E796A12B03Q40416993-DAB734FB-CED0-4FA2-9898-45FF24C5AB10Q40897367-4D295334-481A-4895-88BC-C8712E061D52Q41144584-E6C181EC-B075-4EA3-9C3D-75339A980114Q41345068-0CD7FA9E-E7B8-4B4A-AE5B-CBDA9658BD79Q42408142-6F9EEB9E-EDFB-4B73-AC97-AF750623FE16Q44675776-5BE1569B-008B-4527-BFA1-8C1AC3011834Q45291581-4B9C453D-89C6-43FE-9891-218E192F76B2Q47689139-93A71027-A251-4037-9865-8FF58D3E1359Q47700572-0B7159D3-B104-491B-8638-379B6C3E435EQ47733479-823E7D26-521C-4E63-9B63-1CBF65AA47CAQ47736120-F8921158-B576-46DA-863C-8B785E3D61DEQ47754100-E4ABC9CA-D3F6-49E6-809A-E6263D1A9788Q47858782-D53FC893-B474-4398-8A81-B1AD958CB6E2Q47992176-F47CFBC1-3049-4A8A-939B-09B4F29ED7A7Q49218809-F6E42334-C44D-4CF7-B37C-7BBA5FB08BEEQ49427029-6F28067D-C845-4402-A7C1-00727E2AB151Q49787514-376B55C3-87F1-4EAD-9CB9-64F439D47E40Q50055388-149AD421-B780-4A27-9E5C-5242409E2E1DQ51118505-03E54BC7-4DF0-42A6-B8EE-0CFA02D64652Q51406075-D72BBC71-DE83-4927-AC92-61BDA4806FC2Q51701731-A246E80C-C536-44D0-8F4B-ADB95875B78EQ51713787-BA7D91C8-C6F9-425D-8AE0-B892BF4EAADEQ53154433-A91B8C93-F56D-4919-82B5-CB90952E9406Q53629435-869DC4E3-E6A9-42E6-AB4E-8E0E6E6BEDF1Q54987397-A19673C5-4A63-499C-89E2-AF895893C101Q55175032-1FBED858-7F21-4BBC-9E76-741E8D124AC4Q55438978-BDA95CFB-A7FF-40A2-BCFD-E89CC0459131Q57455138-CD247D41-7995-48EC-B722-2FAA67E8D862Q61809273-4AC690CD-B94D-4ECB-BC6F-27D82392B354Q84523297-B51350D3-F682-4A8C-8CC0-5F7F255F53B6Q86121778-31971312-F972-4843-96B6-36C088A59BAC
P50
description
researcher (ORCID 0000-0002-9632-6691)
@en
name
Paulo Gustavo Kotze
@en
type
label
Paulo Gustavo Kotze
@en
prefLabel
Paulo Gustavo Kotze
@en
P31
P496
0000-0002-9632-6691